MedTrace Logo

Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer

NCT00267488 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2012-07-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out if Hycamtin given weekly is safe and effective for treating your endometrial cancer.

Conditions

Interventions

DRUG

topotecan

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States
  • Canada
  • Hungary

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00267488 on ClinicalTrials.gov